The European Medicines Agency said on 15 November that pan-EU marketing authorizations should be refused for Kizfizo (temozolomide) and Cinainu (allium/citrus/paullinia/cacao), which are two treatments for use in children from Orphelia Pharma and Legacy Healthcare respectively.
Key Takeaways
- The European Medicines Agency this week recommended against pan EU marketing authorization for two drugs – Kizfizo and Cinainu, from Orphelia Pharma and Legacy Healthcare respectively.
- Orphelia and Legacy will be able to ask the EMA to re-examine its decisions
The EMA recommended against approving Kizfizo for treating children with neuroblastoma, saying it was not possible to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?